Kenneth LaMontagne, Ph.D.

Ken has served as our SVP Business Development since June 2022. Dr. LaMontagne brings 22 years of Oncology experience including R&D, Translational Sciences, Commercialization, Business Development & Licensing. Prior to joining IN8Bio, Dr. LaMontagne held senior roles at both large pharma, including Novartis, J&J and BMS, and small biotechnology companies, including Legend and Artisan Bio.

Dr. LaMontagne has done over 50+ due diligences in Oncology covering diverse therapeutic modalities and included small molecules, biologics, cell & gene therapies, spanning pre-clinical to post-marketing assets. Dr. LaMontagne contributed to the first FDA-approved CAR-T therapy, KYMRIAH, while leading the business insights team in the Cell & Gene Therapies Unit at Novartis. After completing his Ph.D. graduate studies at Cold Spring Harbor Laboratory, Dr. LaMontagne was a post-doctoral fellow in the laboratory of the late Dr. Judah Folkman at Harvard Medical School. Dr. LaMontagne has an Executive MBA in Strategy from Rutgers Business School and is currently in the Executive General Management Program in the Wharton School at the University of Pennsylvania.